Literature DB >> 7639408

Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

.   

Abstract

A rapid increase in the incidence of infection and colonization with vancomycin-resistant enterococci (VRE) has been reported from U.S. hospitals in the last 5 years. This increase poses several problems, including a) the lack of available antimicrobials for therapy of infections due to VRE, since most VRE are also resistant to multiple other drugs, e.g., aminoglycosides and ampicillin, previously used for the treatment of infections due to these organisms, and b) the possibility that the vancomycin resistance genes present in VRE may be transferred to other gram-positive microorganisms such as Staphylococcus aureus. An increased risk of VRE infection and colonization has been associated with previous vancomycin and/or multi-antimicrobial therapy, severe underlying disease or immunosuppression, and intra-abdominal surgery. Because enterococci can be found in the normal gastrointestinal or female genital tract, most enterococcal infections have been attributed to endogenous sources within the individual patient. However, recent reports of outbreaks and endemic infections due to enterococci, including VRE, have shown that patient-to-patient transmission of the microorganisms can occur either via direct contact or indirectly via hands of personnel or contaminated patient-care equipment or environmental surfaces.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639408     DOI: 10.1016/0196-6553(95)90104-3

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  32 in total

1.  Pathogenic Mechanisms of Enterococcal Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Methicillin-Resistant Staphylococcus aureus Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  An Update on the Emergence of Glycopeptide Resistance in Enterococci.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 4.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

5.  Rapid diagnosis of bacteremia by universal amplification of 23S ribosomal DNA followed by hybridization to an oligonucleotide array.

Authors:  R M Anthony; T J Brown; G L French
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 6.  Public Health Risks of Multiple-Drug-Resistant Enterococcus spp. in Southeast Asia.

Authors:  Diane Sunira Daniel; Sui Mae Lee; Gary A Dykes; Sadequr Rahman
Journal:  Appl Environ Microbiol       Date:  2015-07-06       Impact factor: 4.792

7.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

8.  Evaluating treatment protocols to prevent antibiotic resistance.

Authors:  S Bonhoeffer; M Lipsitch; B R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 9.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

10.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.